These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 25436769)

  • 1. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.
    Llufriu S; Sepúlveda M; Blanco Y; Marín P; Moreno B; Berenguer J; Gabilondo I; Martínez-Heras E; Sola-Valls N; Arnaiz JA; Andreu EJ; Fernández B; Bullich S; Sánchez-Dalmau B; Graus F; Villoslada P; Saiz A
    PLoS One; 2014; 9(12):e113936. PubMed ID: 25436769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
    Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA
    Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.
    Uccelli A; Laroni A; Ali R; Battaglia MA; Blinkenberg M; Brundin L; Clanet M; Fernandez O; Marriot J; Muraro P; Nabavi SM; Oliveri RS; Radue E; Ramo Tello C; Schiavetti I; Sellner J; Sorensen PS; Sormani MP; Wuerfel JT; Freedman MS;
    Lancet Neurol; 2021 Nov; 20(11):917-929. PubMed ID: 34687636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
    Burt RK; Loh Y; Cohen B; Stefoski D; Balabanov R; Katsamakis G; Oyama Y; Russell EJ; Stern J; Muraro P; Rose J; Testori A; Bucha J; Jovanovic B; Milanetti F; Storek J; Voltarelli JC; Burns WH
    Lancet Neurol; 2009 Mar; 8(3):244-53. PubMed ID: 19186105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
    Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
    JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial.
    Mancardi GL; Sormani MP; Gualandi F; Saiz A; Carreras E; Merelli E; Donelli A; Lugaresi A; Di Bartolomeo P; Rottoli MR; Rambaldi A; Amato MP; Massacesi L; Di Gioia M; Vuolo L; Currò D; Roccatagliata L; Filippi M; Aguglia U; Iacopino P; Farge D; Saccardi R; ;
    Neurology; 2015 Mar; 84(10):981-8. PubMed ID: 25672923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
    Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
    Barkhof F; Hulst HE; Drulovic J; Uitdehaag BM; Matsuda K; Landin R;
    Neurology; 2010 Mar; 74(13):1033-40. PubMed ID: 20200338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial.
    Torkildsen O; Wergeland S; Bakke S; Beiske AG; Bjerve KS; Hovdal H; Midgard R; Lilleås F; Pedersen T; Bjørnarå B; Dalene F; Kleveland G; Schepel J; Olsen IC; Myhr KM
    Arch Neurol; 2012 Aug; 69(8):1044-51. PubMed ID: 22507886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.
    Uccelli A; Laroni A; Brundin L; Clanet M; Fernandez O; Nabavi SM; Muraro PA; Oliveri RS; Radue EW; Sellner J; Soelberg Sorensen P; Sormani MP; Wuerfel JT; Battaglia MA; Freedman MS;
    Trials; 2019 May; 20(1):263. PubMed ID: 31072380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial).
    Mathiasen AB; Jørgensen E; Qayyum AA; Haack-Sørensen M; Ekblond A; Kastrup J
    Am Heart J; 2012 Sep; 164(3):285-91. PubMed ID: 22980293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
    Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
    JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
    O'Connor PW; Li D; Freedman MS; Bar-Or A; Rice GP; Confavreux C; Paty DW; Stewart JA; Scheyer R; ;
    Neurology; 2006 Mar; 66(6):894-900. PubMed ID: 16567708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.
    Stein MS; Liu Y; Gray OM; Baker JE; Kolbe SC; Ditchfield MR; Egan GF; Mitchell PJ; Harrison LC; Butzkueven H; Kilpatrick TJ
    Neurology; 2011 Oct; 77(17):1611-8. PubMed ID: 22025459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
    Kappos L; Li D; Calabresi PA; O'Connor P; Bar-Or A; Barkhof F; Yin M; Leppert D; Glanzman R; Tinbergen J; Hauser SL
    Lancet; 2011 Nov; 378(9805):1779-87. PubMed ID: 22047971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G; Filippi M; Wolinsky JS
    Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.